Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 04 - 27 tags : Trial save search
Altra Industrial Motion Corp. Announces Second Quarter 2021 Dividend
Published: 2021-04-27 (Crawled : 21:00) - globenewswire.com
AIMC | $61.98 -0.02% 0.0% 0
|
Producer Manufacturing
|
| O: 0.29%
H: 1.37%
C: 0.91%
trial
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test is Used in UK Com-COV Clinical Trial to Investigate the T Cell Response in Different Combinations of Approved COVID-19 Vaccines for the First and Second Doses
Published: 2021-04-27 (Crawled : 14:00) - biospace.com/
PKI | $115.24 0.0% 1.6M
|
Health Technology
|
| O: 0.34%
H: 0.32%
C: -0.32%
covid ford test vaccine trial sars-cov-2 t-cell
PPD and Science 37® Strengthen Collaboration to Advance Decentralized Clinical Trials and Accelerate Development
Published: 2021-04-27 (Crawled : 14:00) - biospace.com/
TMO | $554.55 -0.6% 0.0% 1M
|
Health Technology
|
| O: 0.32%
H: 0.19%
C: -1.09%
clinical trials collaboration trial
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
Published: 2021-04-27 (Crawled : 12:00) - biospace.com/
ARAV | $0.0401 4.74% 4M
|
Health Technology
|
| O: 9.37%
H: 7.38%
C: 1.61%
cancer phase 3 ovarian cancer trial
Aldeyra Therapeutics Achieves Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE Clinical Trial of Reproxalap in Allergic Conjunctivitis
Published: 2021-04-27 (Crawled : 12:00) - biospace.com/
ALDX 4 | $3.87 -6.97% -7.49% 720K
|
Health Technology
|
| O: 16.02%
H: 23.74%
C: 15.21%
phase 3 trial reproxalap
Alkermes Initiates ARTISTRY-6 Trial of Nemvaleukin Alfa Monotherapy in Patients With Melanoma
Published: 2021-04-27 (Crawled : 11:00) - investor.alkermes.com
ALKS | $23.78 -1.0% -1.01% 1.6M
|
Health Technology
|
| O: -0.31%
H: 2.59%
C: 0.45%
therapy nemvaleukin trial
ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants
Published: 2021-04-27 (Crawled : 05:00) - obseva.com
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: 0.0%
H: 1.94%
C: -2.9%
bone trial
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.